Cooperative Agreement U01CA288669
Award Date
9/23/24
Completion Date
8/31/29
Dollars Obligated
$357K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Portland, OR 97239, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,352 to Harvard Medical School to identify optimal pre-analytical handling conditions for a functional precision medicine biomarker called RAMP up dynamic BH3 profiling (RUDBP). The goal is to systematically evaluate how different pre-analytical factors like tumor transport, frozen storage, and ex vivo cell culture impact the fidelity and output of the RUDBP biomarker, which...
The National Cancer Institute (NCI) awarded a $401,113 Cooperative Agreement under the Cancer Treatment Research Program (CFDA 93.395) to the University of Washington (UW) to develop a novel "MetaboCore" assay for rapid assessment of drug sensitivity in solid tumor needle biopsies. The goal is to create a robust standard operating procedure (SOP) to evaluate how pre-analytical conditions affect assay performance, including factors like biopsy needle type, transport solution, culture...
The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
This $440,171 Cooperative Agreement was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Fred Hutchinson Cancer Center in Seattle, Washington to systematically investigate and mitigate the impact of pre-analytical variables on the accuracy and reliability of mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid (CSF) from pediatric brain tumor patients participating in clinical trials. The key objectives are to: (1)...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), provides $206,968 to the University of Arizona to develop and validate a gene expression assay called FL24CX. The goal is to use this assay to predict early clinical failure in patients with follicular lymphoma who are treated with immunochemotherapy. The project has two phases: (1) analytical validation of the FL24CX...
The National Cancer Institute (NCI) awarded a $230,010 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Chicago to develop and apply a new epigenome sequencing platform called Glycosylase-Implemented Epigenome Sequencing (GLIMP-SEQ). This platform is designed to enable highly sensitive and specific profiling of 5-methylcytosine (5mC) in degraded clinical samples such as formalin-fixed, paraffin-embedded (FFPE) tissues and cell-free DNA (cfDNA). The grant aims to...
The National Cancer Institute (NCI), under CFDA 93.396 - Cancer Biology Research, awarded a $449,726 project grant to the University of Illinois to develop tools that enable the rapid analysis of changes in protein interactions within living cells. The project aims to significantly improve the sensitivity and temporal resolution of existing proximity labeling approaches used to map dynamic protein interactomes. Key innovations include engineering biotin ligases that can label proteins with...
The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...